MatriSys Bioscience Appoints Jennifer Giottonini Cayer to Its Board of Directors SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience Inc., a clinical-stage specialty biopharmaceutical company developing microbiome-based therapies for the five most common skin...

MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, announced today that it has...

MatriSys Bioscience appoints Magda Marquet, PhD to the Board of Directors SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the...

MatriSys Bioscience, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial with Live Staphylococcus hominis Bacteria for the Treatment of Atopic Dermatitis SAN DIEGO, Aug. 21, 2017 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, today announced that the first patient...

MatriSys Bioscience announces today publication of highly promising results which could translate into clinically meaningful benefits for eighteen million patients with atopic dermatitis SAN DIEGO, Feb. 22, 2017 (GLOBE NEWSWIRE) -- MatriSys Bioscience (MatriSys Bio) is pleased to announce the publication of breakthrough scientific results from the laboratory of Dr. Richard Gallo at...